

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



国药集团
SINOPHARM

國藥控股股份有限公司 SINOPHARM GROUP CO. LTD.*

(A joint stock limited company incorporated in the People's Republic of China with limited liability and carrying on business in Hong Kong as 國控股份有限公司)

(Stock Code: 01099)

OVERSEAS REGULATORY ANNOUNCEMENT INSIDE INFORMATION ANNOUNCEMENT RESIGNATION OF DIRECTOR AND GENERAL MANAGER OF SINOPHARM (CNCM LTD)

This announcement is made by Sinopharm Group Co. Ltd. (the “**Company**”) pursuant to Rules 13.09 (2) and 13.10B of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited and the Inside Information Provisions under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

On 12 January 2021, due to personal reasons, Mr. Li Hui (李輝) resigned as a director, the general manager, a member of the strategy committee and a member of the audit committee of China National Medicines Corporation Ltd. (“**SINOPHARM (CNCM LTD)**”), whose A shares are listed on the Shanghai Stock Exchange, stock code: 600511) with immediate effect. The number of directors of SINOPHARM (CNCM LTD) will not fall below the quorum due to the departure of Mr. Li Hui, which can ensure the board of directors to continue operate as usual.

As of the date of this announcement, the Company holds 54.72% shares of SINOPHARM (CNCM LTD). The directors of the Company believe that the resignation of Mr. Li Hui will not have a material adverse effect on the Company’s operations.

Shareholders of the Company and potential investors are advised to exercise caution when dealing in the shares of the Company.

By order of the Board
Sinopharm Group Co. Ltd.
Wu Yijian
Joint Company Secretary

Shanghai, the PRC
12 January 2021

As at the date of this announcement, the executive directors of the Company are Mr. Yu Qingming and Mr. Liu Yong; the non-executive directors of the Company are Mr. Chen Qiyu, Mr. Ma Ping, Mr. Hu Jianwei, Mr. Deng Jindong, Mr. Wen Deyong, Ms. Guan Xiaohui and Ms. Feng Rongli; and the independent non-executive directors of the Company are Mr. Zhuo Fumin, Mr. Chen Fangruo, Mr. Li Peiyu, Mr. Wu Tak Lung and Mr. Yu Weifeng.

** The Company is registered as a non-Hong Kong company under the Hong Kong Companies Ordinance under its Chinese name and the English name "Sinopharm Group Co. Ltd."*